Latest Infant Formula News

Page 5 of 5

Bubs Australia Posts $2.9m EBITDA Turnaround, Eyes FDA Approval in 2025

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.

Eva Park

22 Jan 2025

Browse the archive

Full archive

Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026

Top